In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Barbara Morgan, Global Vice-President of Pharma and Biotechnology at Kerry.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Barbara, covering:
Believing in herself and being brave enough to leave a company that felt like family in a job that she loved
Why Pharma has proved itself to be indispensable, while the biopharma slowdown is just a blip
The difference between mentors and sponsors, and why you need a blend of both
Lessons for mastering M&A assessment and integration for prioritizing impact

 
Barbara Morgan is Global Vice-President, Pharma, and Biotechnology at Kerry. Prior to that she worked at LLS Health (part of Lubrizol) from 2014 until 2021 and was named General Manager in 2018.
 
With a Ph.D. in Organic Chemistry from the University of Pennsylvania (US), Dr Morgan has more than 15 years of experience in the Life Science industry, covering pharmaceutical, nutraceutical, and medical devices.  She has published numerous articles in peer-reviewed journals and holds patents, including one on the treatment of cancer stem cells.
 
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
 
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.